NeurologyLive®
@neurologylive.bsky.social
290 followers 60 following 48 posts
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments Read our coverage: neurologylive.com
Posts Media Videos Starter Packs
Reposted by NeurologyLive®
mda.org
🚨 Registration is OPEN! 🚨
Join us March 8–11, 2026 in Orlando for the #MDAConference, the leading global event for neuromuscular care & research. 🌍🧬

🔗 Register now: www.mdaconference.org

#MDA #MuscularDystrophy #neuromuscular
neurologylive.bsky.social
🚨 Just launched: our expert interview collection from AAIC 2025!
From novel blood-based biomarkers to tau-targeting therapies and scalable digital tools, top researchers and clinicians shared insights into where Alzheimer care is headed.
🧠 Take a look→
www.neurologylive.com/view/aaic-20...
AAIC 2025: Top Interviews and Key Takeaways
Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments and diagnostics.
www.neurologylive.com
neurologylive.bsky.social
Thank you so much for sharing!
neurologylive.bsky.social
🚨FDA has approved fremanezumab (Ajovy) as the first anti-CGRP preventive treatment for pediatric episodic migraine, expanding care options for children and adolescents aged 6 to 17. Approval was supported by phase 3 SPACE study results.

📰Read more now: www.neurologylive.com/view/fda-app...
FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine
Teva's fremanezumab gains FDA approval for pediatric migraine prevention, offering a vital treatment option for children aged 6-17.
www.neurologylive.com
neurologylive.bsky.social
🧠 #AAIC25: ABvac40, a developing Alzheimer vaccine from Grifols, showed a significant reduction in cognitive decline in a phase 2 trial, and all met primary endpoints with no significant safety concerns 👏

Read more now: www.neurologylive.com/view/alzheim...
Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study
NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.
www.neurologylive.com
neurologylive.bsky.social
Thank you so much for sharing!
neurologylive.bsky.social
🧠 As patients grow up, care must grow with them, and support makes all the difference.

In this new feature, Susan Duberstein, MD, PhD, outlines how continuity of care, patient education, and psychosocial support can smooth this critical journey ❤️

Learn more: www.neurologylive.com/view/the-tra...
The Transition of Care from Pediatric to Adult Neurology: Leaving the Cocoon
Navigating the transition from pediatric to adult neurology involves careful planning, education, and support to ensure optimal care and independence for young adults.
www.neurologylive.com
neurologylive.bsky.social
The EMA’s CHMP has issued a negative opinion on the conditional marketing authorization for Elevidys, Sarepta/Roche’s gene therapy for DMD, citing missed primary endpoints in the EMBARK trial 🧬🤔

💻Read more: www.neurologylive.com/view/ema-iss...
EMA Issues Negative Opinion for Sarepta’s Gene Therapy Elevidys
Roche faces regulatory challenges for Elevidys, an approved gene therapy for Duchenne muscular dystrophy, amid safety concerns and clinical trial setbacks.
www.neurologylive.com
neurologylive.bsky.social
Major neurology trial readouts expected in 2H 2025 may redefine standards of care. Check out our curated list, including PERSEUS (tolebrutinib in PPMS) and azetukalner (for focal seizures), for insights into next-gen therapies 👀

📲Read now: www.neurologylive.com/view/eyeing-...
Eyeing Neurology Drug Development: 2H Trial Readouts to Watch for in 2025
Neurology experts anticipate groundbreaking clinical trial results in 2025, potentially transforming treatment strategies for various neurological conditions.
www.neurologylive.com
neurologylive.bsky.social
🧠💻 Can AI help identify cardiovascular risk in patients with #migraine? New data from #AHS2025 suggest AI-ECG tools, including atrial fibrillation prediction and delta age, may be effective for early detection of adverse vascular events.

🔗Read more now: www.neurologylive.com/view/explori...
Exploring Use of AI Tools for Cardiovascular Risk Prediction in Migraine: Chia-Chun Chiang, MD
The associate professor of neurology at Mayo Clinic Rochester talked about using artificial intelligence-electrocardiogram at baseline to predict adverse vascular events in patients with migraine. [WA...
www.neurologylive.com
neurologylive.bsky.social
🎧🎙️ A special Mind Moments® episode with Stewart Tepper, MD, just dropped! Tune in as we unpack the FDA’s latest #migraine therapy approvals, STS101 and CT-132, and explore what these innovations mean for care, access, and outcomes.

🧠Listen now: www.neurologylive.com/view/special...
Special Episode: Breaking Down the FDA’s Latest Migraine Therapy Approvals with Dr. Stewart Tepper
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Stewart Tepper, MD. [LISTEN TIME: 26 minutes]
www.neurologylive.com
neurologylive.bsky.social
In this video, James Galvin, MD, MPH, explains how the CARM score uses 3 cognitive subtests and machine learning to estimate amyloid risk, helping clinicians assess whether cognitive impairment may be due to Alzheimer's and guide next steps in care 📽️

Watch now: www.neurologylive.com/view/overvie...
Overviewing the Clinical use of the CARM Score in Alzheimer Disease Detection: James Galvin, MD
The professor of neurology at the University of Miami Miller School of Medicine provided context on the clinical use of the Cognivue Amyloid Risk Measure in the context of Alzheimer disease care. [WAT...
www.neurologylive.com
neurologylive.bsky.social
🎙️ Episode 145 of Mind Moments® is live!

In this episode, Joyce Lee-Iannotti, MD, PhD, shares expert insights from the #SLEEP2025 joint meeting on emerging research at the intersection of #stroke, #sleep, and neurorestoration.

🧠 Listen now: www.neurologylive.com/view/episode...
Episode 145: Rewiring Stroke Recovery: What the Glymphatic System Can Teach Us
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joyce Lee-Iannotti, MD, PhD. [LISTEN TIME: 17 minutes]
www.neurologylive.com
neurologylive.bsky.social
📰FDA approves updated label for donanemab (Kisunla) with a new titration schedule to reduce ARIA risk in early-stage #Alzheimers. A promising step toward safer, more targeted anti-amyloid therapy. 🧠

🔗Read more now: www.neurologylive.com/view/fda-app...
FDA Approves Updated Label for Alzheimer Therapy Donanemab to Lower ARIA-E Risk
NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.
www.neurologylive.com
neurologylive.bsky.social
🚨 The FDA has granted priority review to Denali Therapeutics’ tividenofusp alfa, a brain-penetrant therapy for Hunter syndrome (#MPSII). The decision represents the urgent need for treatments targeting neurological symptoms in patients.

🔗Read more now: www.neurologylive.com/view/fda-gra...
FDA Grants Priority Review, Sets PDUFA Date for Hunter Syndrome Treatment Tividenofusp Alfa
Denali Therapeutics advances treatment for Hunter syndrome with FDA's priority review of tividenofusp alfa, targeting brain delivery and improved patient outcomes.
www.neurologylive.com
neurologylive.bsky.social
🔬 Dravet and Lennox-Gastaut may share trial headlines—but they’re clinically distinct.

In our latest podcast episode, Dr. Joseph Sullivan breaks down how to differentiate them, what new research shows, and how trials are evolving.
🎧 Listen now: www.neurologylive.com/view/episode...
Episode 144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joseph Sullivan, MD. [LISTEN TIME: 14 minutes]
www.neurologylive.com
neurologylive.bsky.social
#BREAKING: The FDA has approved an expanded indication on @gehealthcare.bsky.social’s PET imaging agent Vizamyl to include both quantification of amyloid burden for patients with suspected Alzheimer disease (AD) and use in therapy monitoring.

Details: www.neurologylive.com/view/fda-gre...
FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis
The FDA expands Vizamyl's use for Alzheimer’s diagnosis and therapy monitoring, enhancing patient care with precise amyloid quantification.
www.neurologylive.com